Recent progress and challenges for drug-resistant tuberculosis treatment
Control of Mycobacterium tuberculosis infection continues to be an issue, particularly in
countries with a high tuberculosis (TB) burden in the tropical and sub-tropical regions. The …
countries with a high tuberculosis (TB) burden in the tropical and sub-tropical regions. The …
[HTML][HTML] Tuberculosis vaccines–state of the art, and novel approaches to vaccine development
C da Costa, B Walker, A Bonavia - International Journal of Infectious …, 2015 - Elsevier
The quest for a vaccine that could have a major impact in reducing the current global burden
of TB disease in humans continues to be extremely challenging. Significant gaps in our …
of TB disease in humans continues to be extremely challenging. Significant gaps in our …
Mycobacterium tuberculosis infection and vaccine development
J Tang, WC Yam, Z Chen - Tuberculosis, 2016 - Elsevier
Summary Following HIV/AIDS, tuberculosis (TB) continues to be the second most deadly
infectious disease in humans. The global TB prevalence has become worse in recent years …
infectious disease in humans. The global TB prevalence has become worse in recent years …
The effect of adjuvants and delivery systems on Th1, Th2, Th17 and Treg cytokine responses in mice immunized with Mycobacterium tuberculosis-specific proteins
Tuberculosis (TB) is a major health problem of global concern. The control of this disease
requires appropriate preventive measures, including vaccines. In TB, T helper (Th) 1 …
requires appropriate preventive measures, including vaccines. In TB, T helper (Th) 1 …
Vaccination against tuberculosis with whole-cell mycobacterial vaccines
TJ Scriba, SHE Kaufmann… - The Journal of …, 2016 - academic.oup.com
Live attenuated and killed whole-cell vaccines (WCVs) offer promising vaccination strategies
against tuberculosis. A number of WCV candidates, based on recombinant bacillus Calmette …
against tuberculosis. A number of WCV candidates, based on recombinant bacillus Calmette …
A Phase I/II randomized trial of H56: IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients
S Jenum, K Tonby, CS Rueegg, M Rühwald… - Nature …, 2021 - nature.com
Host-directed-therapy strategies are warranted to fight tuberculosis. Here we assess the
safety and immunogenicity of adjunctive vaccination with the H56: IC31 candidate and …
safety and immunogenicity of adjunctive vaccination with the H56: IC31 candidate and …
Recent advances in the development of vaccines for tuberculosis
MJ Ahsan - Therapeutic advances in vaccines, 2015 - journals.sagepub.com
Tuberculosis (Tb) continues to be a dreadful infection worldwide with nearly 1.5 million
deaths in 2013. Furthermore multi/extensively drug-resistant Tb (MDR/XDR-Tb) worsens the …
deaths in 2013. Furthermore multi/extensively drug-resistant Tb (MDR/XDR-Tb) worsens the …
Therapeutic vaccines for tuberculosis—a systematic review
For eradication of tuberculosis (TB) by 2050, the declared aim of the Stop TB Partnership,
novel treatment strategies are indispensable. The emerging epidemic of multi-drug resistant …
novel treatment strategies are indispensable. The emerging epidemic of multi-drug resistant …
Efficacy of Mycobacterium vaccae immunotherapy for patients with tuberculosis: a systematic review and meta-analysis
CY Huang, WY Hsieh - Human vaccines & immunotherapeutics, 2017 - Taylor & Francis
Tuberculosis (TB) is a significant cause of illness and death worldwide. Immunotherapy has
been investigated in the treatment of TB. The purpose of this study was to perform a meta …
been investigated in the treatment of TB. The purpose of this study was to perform a meta …
Novel vaccine candidates against Mycobacterium tuberculosis
S Khoshnood, M Heidary, M Haeili, M Drancourt… - International journal of …, 2018 - Elsevier
Tuberculosis (TB) is now among the top ten causes of mortality worldwide being resulted in
1.7 million deaths including 0.4 million among people with HIV in 2016. The Bacille …
1.7 million deaths including 0.4 million among people with HIV in 2016. The Bacille …